Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 21;10:549. doi: 10.3389/fonc.2020.00549

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Morillon, Smalley Rumfield, Pellom, Sabzevari, Roller, Horn, Jochems, Palena, Greiner and Schlom.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Robust peripheral and intratumoral changes associated with the administration of bintrafusp alfa in the humanized HTB-1 subcutaneous bladder model. (A) Timeline of PBMC engraftment, blood collection, and treatment for subcutaneous HTB-1 tumor-bearing PBMC humanized NSG-β2m^−/− mice. (B) Total serum TGF-β1 levels at 30 min and 6 days post first and second bintrafusp alfa injection (n = 6). (C) Active TGF-β1 levels as a percent of total protein in HTB-1 tumor lysates from control-IgG1 or bintrafusp alfa-treated mice at day 21 post-initiation of bintrafusp alfa treatment (n = 4; *p < 0.05). (D) In vivo localization of AF647-labeled bintrafusp alfa to HTB-1 tumors 2 weeks post i.p. injection.